Trevi Therapeutics, Inc. (TRVI)
| Previous Close | 2.8300 |
| Open | 2.7450 |
| Bid | 2.7200 x 100 |
| Ask | 2.8000 x 100 |
| Day's Range | 2.7400 - 2.8400 |
| 52 Week Range | 0.9700 - 4.0000 |
| Volume | |
| Avg. Volume | 241,875 |
| Market Cap | 194.049M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.
- PR Newswire
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter ended March 31, 2024, as well as provided business updates.
- PR Newswire
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31,
